New Virus-Trapping Gum Could Help Neutralize Herpes Infections
The herpes simplex viruses 1 and 2 (HSV-1/-2) can both cause oral herpes, and despite being one of the most common infections in the world, there are hardly any preventative measures available today to stop the spread.
Some scientists are hopeful that this new anti-viral gum could help fill that gap, especially as research on a herpes vaccine stalls due to a lack of funding. Plus, even if a vaccine is found, there are likely to be breakthrough infections, and chewing gum could help stop those from spreading further.
Current vaccines for influenza, for instance, do not prevent transmission from breakthrough infections, so this gum could be a useful addition for treating orally spread viruses.
The clinical-grade chewy is made from lablab bean powder, ground from the seeds of the Lablab purpureus species, which contain a natural viral trap protein called FRIL.
In experiments using a mechanical mouth, chewing the liquid-soaked gum for 15 minutes released more than 50 percent of the FRIL proteins it contained. Collecting the simulated saliva from this chewing, researchers then tested how well the liquid neutralizes viruses.
Depending on the dose of FRIL to start with, the 'saliva' produced from chewing showed greater than 95 percent neutralization of the H1N1 and H3N2 influenza viruses in the lab.
It also showed up to 75 percent neutralization of the HSV-1 virus and up to 94 percent of the HSV-2 virus – the two most common herpes viruses out there.
Neutralization means that the virus is less likely to infect cells and replicate itself, which would theoretically lead to a reduce viral load and lower chances of transmission.
"These observations augur well for evaluating bean gum in human clinical studies to minimize virus infection/transmission," conclude the authors, led by biochemist Henry Daniell from the University of Pennsylvania.
The new study builds on previous experiments, which found that chewing gum containing certain anti-virals can get rid of more than 95 percent of the SARS-CoV-2 virus in mouth swabs or saliva samples, thereby reducing oral transmission of COVID-19.
Scientists are now testing that 'anti-COVID' chewing gum in clinical trials, but in the meantime, researchers are turning to other viruses to see if the solution works there as well.
For instance, another previous study published in 2020 on lablab beans found that FRIL proteins effectively reduced levels of H5N1 and H7N9 – both of which are influenza viruses that can cause flu in humans and birds.
"Controlling transmission of viruses continues to be a major global challenge," says Daniell.
"A broad spectrum antiviral protein (FRIL) present in a natural food product (bean powder) to neutralize not only human flu viruses but also avian (bird) flu is a timely innovation to prevent their infection and transmission."
The approach seems to be most suitable for reducing viral loads in saliva and the throat area, which are two main sites of oral viral transmission.
The US FDA generally considers lablab bean powder to be safe and non-toxic for human use at low enough levels. Whether it proves to be an effective anti-viral in clinical trials is another matter.
The study was published in Molecular Therapy.
These 7 Common Daily Habits Could Be Damaging Your Kidneys
Statins Could Reduce Dementia Risk Even in People With Low Cholesterol
Review of Thousands of Studies Confirms Best Way to Keep Memory Sharp
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
9 hours ago
- Business Insider
Assembly Biosciences presents Phase 1a data for ABI-5366, ABI-1179
Assembly Biosciences (ASMB) announced Phase 1a clinical and preclinical data for its herpes simplex virus, HSV, helicase-primase inhibitor candidates ABI-5366 and ABI-1179 are featured in multiple poster presentations, including one late-breaker, during the STI & HIV 2025 World Congress, taking place July 26-30, 2025, in Montreal, Canada, as well as in oral and poster presentations at the 49th Annual International Herpesvirus Workshop, taking place July 26-30, 2025, in Berlin, Germany. At the STI & HIV 2025 World Congress, two posters highlight the safety and pharmacokinetic profiles of ABI-5366 and ABI-1179 as observed in healthy participants in Phase 1a studies, supporting their progression to Phase 1b evaluation. The late-breaking poster for ABI-1179, the first scientific presentation of Phase 1a clinical data for this candidate, includes additional new interim data showing that, as was also the case in the ABI-5366 Phase 1a study, no clinically significant food effect was observed. Unblinded safety data for ABI-1179 are also included in this presentation. Elevate Your Investing Strategy:
The Hill
14 hours ago
- The Hill
The FDA must crack down on dangerous knockoff weight-loss drugs
For the first time, there is real hope in the fight against obesity. New data from the Centers for Disease Control and Prevention's National Center for Health Statistics shows that adult obesity rates in the U.S. may finally be flatlining after annual increases since at least 2011. Obesity has long been understood to be the second leading cause of preventable death in America. Neither negative cultural attitudes about weight nor government messaging campaigns about diets have helped curb it. Yet like most insurmountable problems, we are innovating our way out of it. Experts believe a significant part of recent progress is due to powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs. But just as these drugs are changing lives, a dangerous shadow market is growing alongside them. Compounded versions, which are copies of the original drugs made in smaller pharmacies, are flooding websites, med spas and clinics. These versions are often cheaper and easier to get than the real thing. They are also frequently untested, poorly regulated and, in many cases, illegal. The FDA has received more than 500 reports of serious side effects tied to compounded semaglutide and tirzepatide, the active ingredients in Ozempic and Mounjaro. Some patients have landed in the hospital after taking the wrong dose. That is not surprising when you consider that many of these vials come without proper labels or instructions. In 2023 alone, poison control centers received nearly 3,000 semaglutide-related calls, a huge jump from previous years. Many of those cases involved compounded or mislabeled versions of the medication. There are also serious concerns about what is actually in these products. The FDA has warned that some pharmacies are using different chemical forms of semaglutide, called salt forms, that are not approved for use and may not be safe. In April 2025, the agency seized counterfeit Ozempic from the U.S. supply chain after discovering that some vials contained the wrong ingredients or were contaminated with dangerous bacteria. These are not technical violations. They are real risks to people's health. During earlier shortages, compounding was allowed under special circumstances. But those shortages have ended, and the FDA has ordered most pharmacies to stop making these versions. Despite that, many continue to operate in legal gray zones or offer these drugs online. The harm does not stop with safety concerns. This trend also threatens future breakthroughs in obesity care. Companies like Novo Nordisk and Eli Lilly spent years and billions of dollars to develop these treatments. Now, they and others are working on new and even more effective drugs. When unapproved copies flood the market, it becomes harder to fund innovation. If investors cannot count on fair returns, the next generation of such medications may not make it out of the lab. Perhaps the biggest risk is to public trust. When someone has a bad experience with a fake or contaminated version, they may begin to doubt all weight loss innovations. That fear can ripple through the health system, making insurers and doctors more hesitant to support treatments that are helping with the genuine public health emergency of obesity. None of this means that compounding should disappear. It has a place when patients have specific medical needs that cannot be met by the approved versions, such as allergies or special dosing requirements. But what is happening now is not about rare exceptions. The FDA should continue cracking down on compounders that use unapproved ingredients or sell mislabeled products disguised as 'research chemicals.' At the same time, insurers and lawmakers need to make the real thing more affordable by removing middlemen such as pharmacy benefit managers. No one should have to choose between risking their health and going broke. We are finally making progress against a disease that affects nearly half the country and has stumped policymakers and advocates for decades. But progress is fragile. Unregulated versions of GLP-1s cannot be allowed to dominate the market. We risk undoing the progress reported by the CDC in the fight against obesity, and if we get this right, the trend could be reversed. That means longer lives for more people, lived in dignity and to the fullest.
Epoch Times
a day ago
- Epoch Times
Nature's First Aid: How Herbs Speed Up Fracture Healing and Soothe Pain
While crossing the street in laced-up heels, Erica Kuo—a certified clinical aromatherapist and herbal aromatherapy educator—tripped when one of her laces came loose. Acting quickly, she reached into her bag and applied arnica cream, an herbal salve she always carries for emergencies. A hospital visit later confirmed a fractured toe, and a fixation device was used to stabilize it. During the three-month recovery period, Kuo relied on herbal teas, botanical oils, and creams, which she applied directly to the injury, to relieve swelling and pain while supporting her body's natural healing process. Natural remedies, Kuo noted in an episode on Health 1+1, can effectively aid recovery and provide relief, alleviating the need for conventional painkillers.
